Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization

Journal of Peptide Science

Volumn 18, Issue 4, 2012, Pages 215-223

  Perera, Yasser ^a   Costales, Heydi C ^a   Diaz, Yakelin ^a   Reyes, Osvaldo ^a   Farina, Hernan G ^b   Mendez, Lissandra ^a   Gómez, Roberto E ^c   Acevedo, Boris E ^a   Gomez, Daniel E ^b   Alonso, Daniel F ^b   Perea, Silvio E ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c ELEA Laboratories   (Argentina)

Author keywords

B23 nucleophosmin; Cell penetrating peptide; CIGB 300; CK2; P15 Tat

Indexed keywords

ANTINEOPLASTIC AGENT; CIGB 300; NUCLEOPHOSMIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL CYCLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VIVO STUDY; NUCLEAR LOCALIZATION SIGNAL; NUCLEOLAR LOCALIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASEIN KINASE II; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEOLUS; CELL PROLIFERATION; HUMANS; INHIBITORY CONCENTRATION 50; NUCLEAR PROTEINS; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

ANIMALIA;

EID: 84858861219     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1432     Document Type: Article

References (22)

1. Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, López E, Falcón V, Alonso DF. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (Casein Kinase 2). Cancer Res. 2004; 64: 7127-7129.
2. Prudent R, Cochet C. New protein kinase CK2 inhibitors: jumping out of the catalytic box. Chem. Biol. 2009; 16: 112-120.
3. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 2002; 12: 226-230.
4. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim. Biophys. Acta 2008; 1784: 33-47.
5. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim. Biophys. Acta 2010; 1804: 499-504.
6. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 2005; 57: 579-596.
7. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003; 17: 349-368.
8. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat. Rev. Cancer 2006; 6: 493-505.
9. Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L, Gómez RE, Acevedo B, Alonso DF, Perea SE. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Mol. Cancer Ther. 2009; 8: 1189-1196.
10. Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, Lopez-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, Lopez E, Falcon V, Hernandez I, Solares M, Santana A, Diaz A, Ramos T, Lopez C, Ariosa J, Gonzalez LJ, Garay H, Gomez R, Alonso DF, Sigman H, Herrera L, Acevedo B. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol. Cell. Biochem. 2008; 316: 163-167.
11. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 2007; 24: 1977-1992.
12. Cell Line Verification Test Recommendations, ATCC Technical Bulletin No. 8 2008.
13. Boyd MR. The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985-1995, in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press, Totowa, NJ USA, 1997.
14. Laemmli UK Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
15. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 2001; 1515: 101-109.
16. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 2005; 57: 529-45.
17. Langel U. Handbook of Cell-Penetrating Peptides. (Eds.)Taylor & Francis Group. Stockholm, Sweden, 2006; 29-43.
18. Tünnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 2006; 20: 1775-1784.
19. Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene 2008; 27: 4210-4220.
20. Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y, Yang C. RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene 2009; 28: 4201-4211.
21. Perera Y, Farina HG, Hernandez I, Mendoza O, Serrano JM, Reyes O, Gomez DE, Gomez RE, Acevedo BE, Alonso DF, Perea SE. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int. J. Cancer 2008; 122: 57-62.
22. URL: [last accessed July 2011]